Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Juby A Jacob-Nara

Showing results (1-10 of 93) with videos related to

Pageof 10
Sort By:
Allergy and Asthma Proceedings|July 4, 2014
Current Allergic Rhinitis Experiences Survey (CARES): Consumers' awareness, attitudes and practicesLeonard M Fromer, Michael S Blaiss, Juby A Jacob-Nara, et al.
Allergy and Asthma Proceedings|July 4, 2014
Current Allergic Rhinitis Experiences Survey (CARES): Health-care practitioners' awareness, attitudes and practicesMichael S Blaiss, Leonard M Fromer, Juby A Jacob-Nara, et al.
Advances in Therapy|January 10, 2023
Dupilumab-Treated Patients with Asthma in the Real World: The RAPID Global RegistryRebecca Gall, Neal Jain, Weily Soong, et al.
Frontiers in Immunology|May 1, 2024
The interleukin-4/interleukin-13 pathway in type 2 inflammation in chronic rhinosinusitis with nasal polypsClaus Bachert, Alexandra Hicks, Simon Gane, et al.
Expert Review of Gastroenterology & Hepatology|February 5, 2025
Dupilumab is efficacious for eosinophilic esophagitis irrespective of prior swallowed budesonide or fluticasone, or prior treatments used alongside swallowed topical corticosteroids: results from the phase 3, randomized, placebo-controlled, LIBERTY EoE TREET trialAlbert J Bredenoord, Evan S Dellon, Christoph Schlag, et al.
Clinical & Translational Immunology|June 10, 2024
Dupilumab improves outcomes in patients with chronic rhinosinusitis with nasal polyps irrespective of gender: results from the SINUS-52 trialWytske J Fokkens, Claus Bachert, Claire Hopkins, et al.
Allergy and Asthma Proceedings|July 22, 2023
Dupilumab efficacy in patients with chronic rhinosinusitis with nasal polyps with and without allergic rhinitisAnju T Peters, Martin Wagenmann, Jonathan A Bernstein, et al.
Advances in Therapy|October 9, 2024
Reduced Sense of Smell in Patients with Severe Chronic Rhinosinusitis and its Implications for Diagnosis and Management: A Narrative ReviewZachary M Soler, Scott Nash, Andrew P Lane, et al.
Journal of Comparative Effectiveness Research|February 11, 2026
Treatment burden and healthcare resource utilization in patients with chronic rhinosinusitis with nasal polyps who did or did not undergo functional endoscopic sinus surgery: a US real-world retrospective cohort studyDanielle L Isaman, Mark Corbett, Stella E Lee, et al.
Pediatric Pulmonology|July 17, 2024
Dupilumab 200 mg was efficacious in children (6-11 years) with moderate-to-severe asthma for up to 2 years: EXCURSION open-label extension studyWanda Phipatanakul, Christian Vogelberg, Leonard B Bacharier, et al.
Pageof 10

Showing results (1-10 of 93) with videos related to

Sort By:
Pageof 10
Allergy and Asthma Proceedings|July 4, 2014
Current Allergic Rhinitis Experiences Survey (CARES): Consumers' awareness, attitudes and practicesLeonard M Fromer, Michael S Blaiss, Juby A Jacob-Nara, et al.
Allergy and Asthma Proceedings|July 4, 2014
Current Allergic Rhinitis Experiences Survey (CARES): Health-care practitioners' awareness, attitudes and practicesMichael S Blaiss, Leonard M Fromer, Juby A Jacob-Nara, et al.
Advances in Therapy|January 10, 2023
Dupilumab-Treated Patients with Asthma in the Real World: The RAPID Global RegistryRebecca Gall, Neal Jain, Weily Soong, et al.
Frontiers in Immunology|May 1, 2024
The interleukin-4/interleukin-13 pathway in type 2 inflammation in chronic rhinosinusitis with nasal polypsClaus Bachert, Alexandra Hicks, Simon Gane, et al.
Expert Review of Gastroenterology & Hepatology|February 5, 2025
Dupilumab is efficacious for eosinophilic esophagitis irrespective of prior swallowed budesonide or fluticasone, or prior treatments used alongside swallowed topical corticosteroids: results from the phase 3, randomized, placebo-controlled, LIBERTY EoE TREET trialAlbert J Bredenoord, Evan S Dellon, Christoph Schlag, et al.
Clinical & Translational Immunology|June 10, 2024
Dupilumab improves outcomes in patients with chronic rhinosinusitis with nasal polyps irrespective of gender: results from the SINUS-52 trialWytske J Fokkens, Claus Bachert, Claire Hopkins, et al.
Allergy and Asthma Proceedings|July 22, 2023
Dupilumab efficacy in patients with chronic rhinosinusitis with nasal polyps with and without allergic rhinitisAnju T Peters, Martin Wagenmann, Jonathan A Bernstein, et al.
Advances in Therapy|October 9, 2024
Reduced Sense of Smell in Patients with Severe Chronic Rhinosinusitis and its Implications for Diagnosis and Management: A Narrative ReviewZachary M Soler, Scott Nash, Andrew P Lane, et al.
Journal of Comparative Effectiveness Research|February 11, 2026
Treatment burden and healthcare resource utilization in patients with chronic rhinosinusitis with nasal polyps who did or did not undergo functional endoscopic sinus surgery: a US real-world retrospective cohort studyDanielle L Isaman, Mark Corbett, Stella E Lee, et al.
Pediatric Pulmonology|July 17, 2024
Dupilumab 200 mg was efficacious in children (6-11 years) with moderate-to-severe asthma for up to 2 years: EXCURSION open-label extension studyWanda Phipatanakul, Christian Vogelberg, Leonard B Bacharier, et al.
Pageof 10